Dan, Rotem http://orcid.org/0000-0003-4341-330X
Whitton, Alexis E. http://orcid.org/0000-0002-7944-2172
Treadway, Michael T. http://orcid.org/0000-0002-5913-114X
Rutherford, Ashleigh V.
Kumar, Poornima http://orcid.org/0000-0002-9548-3281
Ironside, Manon L.
Kaiser, Roselinde H.
Ren, Boyu
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Funding for this research was provided by:
Weizmann Institute of Science
Department of Health | National Health and Medical Research Council (GNT 2017521)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH101521, R37 MH068376)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 20 October 2023
Revised: 27 January 2024
Accepted: 1 March 2024
First Online: 13 March 2024
Competing interests
: Over the past 3 years, Dr. Pizzagalli has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sage Therapeutics, Sama Therapeutics, Sunovion, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and from Alkermes; he has received research funding from the Bird Foundation, Brain and Behavior Research Foundation, Dana Foundation, Wellcome Leap, Millennium Pharmaceuticals, and NIMH; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software; he has a financial interest in Neumora Therapeutics, which has licensed the copyright to the human version of the probabilistic reward task through Harvard University. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. All other authors have no conflicts of interest or relevant disclosures.